



Under the America Invents Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/562,852
(use as many sheets as necessary)				Filing Date	April 19, 2006
Sheet 1 of 12				First Named Inventor	Ehud GAZIT
				Art Unit	1649
				Examiner Name	DUTT, ADITI
				Attorney Docket Number	31230
U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date DD-MMM-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	2002/006954	17-Jan-2002	Hensley et al.	
	2	2003/0130484	10-Jul-2003	Gordon et al.	
	3	2003/0158237	21-Aug-2003	Saragovi et al.	
	4	2005/0069950	31-Mar-2005	Haynie	
	5	2006/0234947	19-Oct-2006	Gazit	
	6	2007/0135334	14-Jun-2007	Gazit	
	6 a	2007/298043	27-Dec-2007	Gazit et al.	
	7	4,299,917	10-Nov-1981	Berger et al.	
	8	5,304,470	19-Apr-1994	Fischer et al.	
	9	5,332,648	26-Jul-1994	Kihara et al.	
	10	5,556,744	17-Sep-1996	Weiner et al.	
	11	5,916,642	29-Jun-1999	Chang	
	12	6,162,828	19-Dec-2000	Fukuda et al.	
	13	6,261,569	17-Jul-2001	Comis et al.	
	14	6,361,861	26-Mar-2002	Gao et al.	
	15	6,613,875	02-Sep-2003	Ghadiri	
	16	6,689,753	10-Feb-2004	Soto-Jara	
	17	6,858,318	22-Feb-2005	Kogiso et al.	
	18	6,976,639	20-Dec-2005	Williams et al.	
FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Documents	Publication Date DD-MMM-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ² Number ³ Kind Code ⁴ (if known)			
	19	DE 10043282	28-Mar-2002	Heininger	
	20	JP 10-245342	14-Sep-1998	Araya et al.	
	21	DE 3412445	10-Oct-1985	Meyer	
	22	WO 01/10457	15-Feb-2001	Vahne	
	23	WO 01/49281	12-Jul-2001	Castillo et al.	
	24	WO 01/49307	12-Jul-2001	Castillo et al.	
	25	WO 01/93836	13-Dec-2001	Bouliskas et al.	
	26	WO 02/072086	19-Sep-2002	Suzuki	
	27	WO 03/013442	20-Feb-2003	Castillo et al.	
	28	WO 2004/052773	24-Jun-2004	Reches et al.	
	29	WO 2005/020809	10-Mar-2005	Owen et al.	
Examiner Signature	/Aditi Dutt/			Date Considered	11/21/2008

¹ EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional).

³ See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3).

⁵ Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3).

⁶ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁷ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁸ Applicant is to place a check mark here if English language translation is attached.

⁹ This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/562,852
Filing Date	April 19, 2006
First Named Inventor	Ehud GAZIT
Art Unit	1649
Examiner Name	DUTT, ADITI
Attorney Docket Number	31230

Sheet

2

Q

13

Attorney Docket Number

31230

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature	/Aditi Dutt/	Date Considered	11/21/2008
-----------------------	--------------	--------------------	------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered.

Include copy of copy of this form with next communication to applicant

[†] Applicant's unique citation designation number (optional)

² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3).

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3)

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English language translation is attached

Applicant is to place a check mark here if English language translation is attached

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 127 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. The time required will depend upon the individual case. **Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /A.D./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number	10/562,852
		Filing Date	April 19, 2006
		First Named Inventor	Ehud GAZIT
		Group Art Unit	1649
		Examiner Name	DUIT, ADITI
Sheet	3	Of	12
		Attorney Docket Number	31230
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	35	Akazome et al. "Enantioselective Inclusion of Methyl Phenyl Sulfoxides and Benzyl Methyl Sulfoxides by (R)-Phenylglycyl-(R)-Phenylglycine and the Crystal Structures of the Inclusion Cavities", <i>Journal of Organic Chemistry</i> , 65(1): 68-76, 2000.	
	36	Anguano et al. "Protofibrillar Islet Amyloid Polypeptide Permeabilizes Synthetic Vesicles by A Pore-Like Mechanism That May Be Relevant to Type II Diabetes", <i>Biochemistry</i> , 41: 11338-11343, 2002.	
	37	Arvinte et al. "The Structure and Mechanism of Formation of Human Calcitonin Fibrils", <i>The Journal of Biological Chemistry</i> , 268(9): 6415-6422, 1993.	
	38	Austin et al. "Medical Progress: Calcitonin. Physiology and Pathophysiology", <i>The New England Journal of Medicine</i> , 304(5): 269-278, 1981.	
	39	Balaran "De Novo Design: Backbone Conformational Constraints in Nucleating Helices and β -Hairpins", <i>Journal of Peptide Research</i> , 54: 195-199, 1999.	
	40	Balbach et al. "Supramolecular Structure in Full-Length Alzheimer's β -Amyloid Fibrils: Evidence for A Parallel β -Sheet Organization From Solid-State Nuclear Magnetic Resonance", <i>Biophysical Journal</i> , 83: 1205-1216, 2002.	
	41	Bauer et al. "Interfacial Adsorption and Aggregation Associated Changes in Secondary Structure of Human Calcitonin Monitored by ATR-FTIR Spectroscopy", <i>Biochemistry</i> , 33: 12276-12282, 1994.	
	42	Benveniste et al. "Homology of Calcitonin With the Amyloid-Related Proteins", <i>Journal of Endocrinological Investigation</i> , 17: 119-122, 1994.	
	43	Berger et al. "Calcitonin-Like Immunoreactivity of Amyloid Fibrils in Medullary Thyroid Carcinomas", <i>Virchows Archiv A Pathological Anatomy and Histopathology</i> , 412: 543-551, 1988.	
	44	Berson et al. "Proprotein Convertase Cleavage Liberates A Fibrillogenic Fragment of A Resident Glycoprotein to Initiate Melanosome Biogenesis", <i>Journal of Cell Biology</i> , 161(3): 521-533, 2003.	
	45	Bird et al. "Single-Chain Antigen-Binding Proteins", <i>Science</i> , 242(4877): 423-426, 1988.	
	46	Boerner et al. "Production of Antigen-Specific Human Monoclonal Antibodies From In Vitro-Primed Human Splenocytes", <i>The Journal of Immunology</i> , 147(1): 86-95, 1991.	
	47	Bong et al. "Self-Assembling Organic Nanotubes", <i>Angewandte Chemie, International Edition</i> , 40:988-1011, 2001.	
Examiner Signature	/Aditi Duit/		Date Considered 11/21/2008

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional)

³ See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04 3. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3)

⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document

⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible

⁷ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22311-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22311-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449A/PTO		Complete if Known	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/562,852
		Filing Date	April 19, 2006
		First Named Inventor	Ehud GAZIT
		Art Unit	1649
		Examiner Name	DUITT, ADITI
Sheet	4	Of	12
		Attorney Docket Number	31230
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	
	48	Chapman et al. "Role of Escherichia Coli Curli Operons in Directing Amyloid Fiber Formation", Science, 295(5556): 851-855, 2002, Abstract.	
	49	Cherny et al. "The Formation of Escherichia Coli Curli Amyloid Fibrils is Mediated by Prion-Like Peptide Repeats", Journal of Molecular Biology, 352(2): 245-252, 2005.	
	50	Cherny et al. "The YefM Antitoxin Defines A Family of Natively Unfolded Proteins", The Journal of Biological Chemistry, 279(9): 8252-8261, 2004.	
	51	Choplin "Computers and the Medicinal Chemist", Comprehensive Medicinal Chemistry, 4(Chap.17.2): 33-58, 1990.	
	52	Chou et al. "Conformational Parameters for Amino Acids in Helical, β -Sheet, and Random Coil Regions Calculated From Proteins", Biochemistry, 13(2): 211-222, 1974.	
	53	Chou et al. "Empirical Predictions of Protein Conformation", Annual Reviews in Biochemistry, 47: 251-276, 1978.	
	54	Claessens et al. "A Novel Class of Secreted Hydrophobic Proteins is Involved in Aerial Hyphae Formation in Streptomyces Coelicolor by Forming Amyloid-Like Fibrils", Genes & Development, 17: 1714-1726, 2003.	
	55	Claessens et al. "Review Commentary: π - π Interactions in Self-Assembly", Journal of Physical Organic Chemistry, 10: 254-272, 1997.	
	56	Clark et al. "Self-Assembling Cyclic β -Peptide Nanotubes as Artificial Transmembrane Ion Channels", Journal of the American Chemical Society, JACS, 120: 651-656, 1998.	
	57	Cole et al. "The EBV-Hybridoma Technique and Its Application to Human Lung Cancer", Monoclonal Antibodies and Cancer Therapy, Proceedings of the Roche-UCLA Symposium, Park City, Utah, P.77-96, 1985.	
	58	Copp "Endocrine Regulation of Calcium Metabolism", Annual Reviews in Physiology, 32: 61-86, 1970.	
	59	Elliot et al. "The Chaplins: A Family of Hydrophobic Cell-Surface Proteins Involved in Aerial Mycelium Formation in Streptomyces Coelicolor", Genes & Development, 17: 1727-1740, 2003.	
Examiner Signature	/Aditi Dutt/		Date Considered 11/21/2008

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional)

2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3)

4 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3)

5 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

6 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible

7 Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Substitute for form 1449A/PTO		Complete if Known	
		Application Number	10/562,852
		Filing Date	April 19, 2006
		First Named Inventor	Ehud GAZIT
		Art Unit	1649
		Examiner Name	DUTT, ADITI
		Attorney Docket Number	31230
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			
Sheet	5	Of	12
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	†
	60	Engelberg-Kulka et al. "Bacterial Programmed Cell Death Systems as Targets for Antibiotics", Trends in Microbiology, Vol. 12 (2): P. 66-71, 2004.	
	61	Findis et al. "Modified-Peptide Inhibitors of Amyloid β -Peptide Polymerization", Biochemistry, 38: 6791-6800, 1999.	
	62	Fingl et al. "Introduction: General Principles", The Pharmacological Basis of Therapeutics, 5th Ed., Sec. I (Chap. 1): 1-53, 1975.	
	63	Fishwild et al. "High-Avidity Hum IgGk Monoclonal Antibodies From A Novel Strain of Minilocus Transgenic Mice", Nature Biotechnology, 14: 845-851, 1996.	
	64	Forloni et al. "Anti-Amyloidogenic Activity of Tetracyclines: Studies in Vitro", FEBS Letters, 487(3): 404-407, 2001. Figs. 1,3.	
	65	Gazit "Mechanisms of Amyloid Fibril Self-Assembly and Inhibition Model Short Peptides as A Key Research Tool", The FEBS Journal, 272: 5971-5978, 2005.	
	66	Gazit "Mechanistic Studies of Process of Amyloid Fibrils Formation by the Use of Peptide Fragments and Analogues: Implications for the Design of Fibrillation Inhibitors", Current Medicinal Chemistry, 9: 1725-1735, 2002.	
	67	Ghadiri et al. "Artificial Transmembrane Ion Channels From Self-Assembling Peptide Nanotubes", Nature, 369(6478): 301-304, 1994.	
	68	Gillard et al. "Controlling Self-Assembly", Chemical European Journal, 3(12): 1933-1940, 1997.	
	69	Görlitz "Nanotube Formation by Hydrophobic Dipeptides", Chemistry, 7(23): 5153-5159, 2001, Abstract.	
	70	Grady et al. "Axe-Txc, A Broad-Spectrum Proteic Toxin-Antitoxin System Specified by a Multidrug-Resistant, Clinical Isolate of Enterococcus Faecium", Molecular Microbiology, Vol. 47(5): P. 1419-1432, 2003.	
	71	Grateau "[Coli's Curli or How Amyloid Can be Physiological.]", Médecine Sciences, 18(6-7): P.664, 2002.	
	72	Häggqvist et al. "Medin: An Integral Fragment of Aortic Smooth Muscle Cell-Produced Lactadherin Forms the Most Common Human Amyloid", Proc. Natl. Acad. Sci. USA, 96: 8669-8674, 1999.	
	73	Haldar et al. "First Crystallographic Signature of the Highly Ordered Supramolecular Helical Assemblage From A Tripeptide Containing A Non-Coded Amino Acid", Tetrahedron Letters, 43(14): 2653-2656, 2002. Abstract.	
Examiner Signature	/Aditi Dutt/		Date Considered 11/21/2008

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered.

† Include copy of copy of this form with next communication to applicant.

‡ Applicant's unique citation designation number (optional).

² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁷ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO		Complete if Known	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/562,852
		Filing Date	April 19, 2006
		First Named Inventor	Ehud GAZIT
		Art Unit	1649
		Examiner Name	DUTTI, ADITI
Sheet	6	Of	12
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	r ²
	74	Harlow et al. "Antibodies: A Laboratory Manual", Cold Spring Harbor Laboratory, P.III-IX, 1988.	
	75	Harrison et al. "Amyloid Peptides and Proteins in Review", Reviews in Physiology, Biochemistry and Pharmacology, 159: 1-77, 2007.	
	76	Hartgerink et al. "Peptide Nanotubes and Beyond", Chemistry European Journal, 4(8): 1367-1372, 1998. Abstract.	
	77	Holmes et al. "Extensive Neurite Outgrowth and Active Synapse Formation on Self-Assembling Peptide Scaffolds", Proc. Natl. Acad. Sci. USA, 97(12): 6728-6733, 2000.	
	78	Hoogenboom et al. "By-Passing Immunisation. Human Antibodies From Synthetic Repertoires of Germline V _H Gene Segments Rearranged In Vitro", Journal of Molecular Biology, 227: 381-388, 1992.	
	79	Hoyle et al. "Pseudomonas Aeruginosa Biofilm as A Diffusion Barrier to Piperacillin", Antimicrobial Agents and Chemotherapy, 36(9): 2054-2056, 1992.	
	80	Huang et al. "A Review on Polymer Nanofibers by Electrospinning and Their Applications in Nanocomposites", Composites Science and Technology, 63: 2223-2253, 2003.	
	81	Inbar et al. "Localization of Antibody-Combining Sites Within the Variable Portions of Heavy and Light Chains", Proc. Natl. Acad. Sci. USA, 69(9): 2659-2662, 1972.	
	82	Jack et al. "The Organization of Aromatic Side Groups in An Amyloid Fibril Probed by Solid-State 2H and 19F NMR Spectroscopy", Journal of the American Chemical Society, JACS, 128: 8098-8099, 2006.	
	83	Jayawarna et al. "Nanostructured Hydrogels for Three-Dimensional Cell Culture Through Self-Assembly of Fluorenylmethoxycarbonyl-Dipeptides", Advanced Materials, 18: 611-614, 2006.	
	84	Jin "Electrospinning Bombyx Mori Silk With Poly (Ethylene Oxide)" Biomacromolecules, 3: 1233-1239, 2002.	
	85	Jones et al. "Replacing the Complementarity-Determining Regions in A Human Antibody With Those From A Mouse", Nature, 321: 522-525, 1986.	
Examiner Signature	/Aditi Dutt/		Date Considered 11/21/2008

* EXAMINER. Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional).

² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO			Complete if Known		
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	10/562,852	
			Filing Date	April 19, 2006	
			First Named Inventor	Ehud GAZIT	
			Art Unit	1649	
			Examiner Name	DUTT, ADITI	
Sheet	7	Of	12	Attorney Docket Number	31230
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	86	Kamihira et al. "Conformational Transitions and Fibrillation Mechanism of Human Calcitonin as Studied by High-Resolution Solid-State 13C NMR [in Process Citation]", Protein Science, 9: 867-877, 2000.			
	87	Kanaori et al. "Study of human Calcitonin Fibrillation by Proton Nuclear Magnetic Resonance Spectroscopy", Biochemistry, 34: 12138-12143, 1995.			
	88	Kaplan "Fibrous Proteins-Silk as A Model System", Polymer Degradation and Stability, 59: 25-32, 1998.			
	89	Kapurniotu et al. "Structure-Based Design and Study of Non-Amyloidogenic, Double N-Methylated IAPP Amyloid Core Sequences as Inhibitors of IAPP Amyloid Formation and Cytotoxicity", Journal of Molecular Biology, 315: 339-350, 2002.			
	90	Kedar et al. "In Vitro Synthesis of 'Amyloid' Fibrils From Insulin, Calcitonin and Parathormone", Israel Journal of Medical Science, 12(10): 1137-1140, 1976.			
	91	Kubik "High-Performance Fibers From Spider Silk", Angewandte Chemie, International Edition, 41(15): 2721-2723, 2002.			
	92	Kyte et al. "A Simple Method for Displaying the Hydropathic Character of A Protein", Journal of Molecular Biology, 157: 105-132, 1982.			
	93	Lansbury "Following Nature's Anti-Amyloid Strategy", Nature Biotechnology, 19(2): 112-113, 2001. P.112, Left-Hand Col., Paragraph 1 - Middle Col., Paragraph 1.			
	94	Larrick et al. "PCR Amplification of Antibody Genes", Methods: A Companion to Methods in Enzymology, 2(2): 106-110, 1991.			
	95	Lazaris et al. "Spider Silk Fibers Spun From Soluble Recombinant Silk Produced in Mammalian Cells", Science, 295: 472-476, 2002. P.474-475.			
	96	Lee et al. "Virus-Based Fabrication of Micro- and Nanofibers Using Electrospraying" Nano Letters, 4(3): 387-390, 2004.			
	97	Liao et al. "Triphenylmethane Dyes as Inhibitors of Reverse Transcriptase RNA Polymerase and Protein Synthesis: Structure Activity Relationships", Journal of Medicinal Chemistry, 18(1): 117-120, 1975. Abstract.			
	98	Lonberg et al. "Antigen-Specific Human Antibodies From Mice Comprising Four Distinct Genetic Modifications", Nature, 368(6474): 856-859, 1994.			
Examiner Signature	/Aditi Dutt/			Date Considered	11/21/2008

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered.

Include copy of copy of this form with next communication to applicant

¹ Applicant's unique citation designation number (optional).² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. (DO NOT SEND) FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known			
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number	10/562,852		
		Filing Date	April 19, 2006		
		First Named Inventor	Ehud GAZIT		
		Art Unit	1649		
		Examiner Name	DUTT, ADITI		
Sheet	8	Of	12	Attorney Docket Number	31230
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	99	Lonberg et al. "Human Antibodies From Transgenic Mice", International Review of Immunology, 13: 65-93, 1995.			
	100	Lowe et al. "Structure-Function Relationships for Inhibitors of β -Amyloid Toxicity Containing the Recognition Sequence KLVFF", Biochemistry, 40: 7882-7889, 2001.			
	101	Lyon et al. "Self-Assembly and Gelation of Oxidized Glutathione in Organic Solvents", Journal of the American Chemical Society, 123: 4408-4413, 2001.			
	102	Mah et al. "A Genetic Basis for Pseudomonas Aeruginosa Biofilm Antibiotic Resistance", Nature, 426: 306-310, 2003.			
	103	Mahler et al. "Rigid, Self-Assembled Hydrogel Composed of A Modified Aromatic Dipeptide", Advanced Materials, 18(11): 1365-1370, 2006.			
	104	Maji et al. "Fibril-Forming Model Synthetic Peptides Containing 3-Aminophenylacetic Acid", Tetrahedron, 58(43): 8695-8702, 2002, Abstract.			
	105	Marks et al. "By-Passing Immunization - Human Antibodies from V-Gene Libraries Displayed on Phage", Journal of Molecular Biology, 222: 581-597, 1991.			
	106	Marks et al. "By-Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling", Bio/Technology, 10: 779-783, 1992.			
	107	Matsui et al. "Crystalline Glycylglycine Bolaamphiphile Tubules and Their pH-Sensitive Structural Transformation" The Journal of Physical Chemistry B, 104(15): 3384-3386, 2000.			
	108	Maury et al. "Creation of Amyloid Fibrils From Mutant ASN187 Gelsolin Peptides", Biochemical and Biophysical Research Communications, 183(1): 227-231, 1992.			
	109	McGaughey et al. "n-Stacking Interactions", The Journal of Biological Chemistry, 273(25): 15458-15463, 1998.			
	110	Meluleni et al. "Mucoic Pseudomonas Aeruginosa Growing in A Biofilm in Vitro are Killed by Opsonic Antibodies to the mucoic Exopolysaccharide Capsule but Not by Antibodies Produced During Chronic Lung Infection in Cystic Fibrosis Patients ^{1, 2} ", Journal of Immunology, 155: 2029-2038, 1995.			
	111	Morrison "Success in Specification", Nature, 368(6474): 812-813, 1994.			
	112	Mosmann "Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assays", Journal of Immunological Methods, 65: 55-63, 1983.			
Examiner Signature	/Aditi Dutt/			Date Considered	11/21/2008

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional).

² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁷ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14, this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO			Complete if Known		
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	10/562,852	
			Filing Date	April 19, 2006	
			First Named Inventor	Ehud GAZIT	
			Art Unit	1649	
			Examiner Name	DUTT, ADITI	
Sheet	9	Of	12	Attorney Docket Number	31230
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			1 ²
	113	Mosselman et al. "The Complete Islet Amyloid Polypeptide Precursor Is Encoded by Two Exons", FEBS Letters, 247: 154-158, 1989, Database Accession No. S04016.			
	114	Murphy et al. "Biofilm Formation by Nontypeable Haemophilus Influenzae: Strain variability, Outer Membrane Antigen Expression and Role of pili", BMC Microbiology, 2(7): 1471-2180, 2002.			
	115	Mutter "Studies on the Coupling Rates in Liquid-Phase Peptide Synthesis Using Competition Experiments", International Journal of Peptide Protein Research, 13: 274-277, 1979.			
	116	Neuberger "Generating High-Avidity Human Mabs in Mice", Nature Biotechnology, 14: 826, 1996.			
	117	Nicolaus "Symbiotic Approach to Drug Design", Decision Making in Drug Research, P.173-186, 1983.			
	118	Offen et al. "A Low Molecular Weight Copper Chelator Crosses the Blood-Brain Barrier and Attenuates Experimental Autoimmune Encephalomyelitis", Journal of Neurochemistry, 89: 1241-1251, 2004.			
	119	Pack et al. "Improved Bivalent Miniantibodies, With Identical Avidity as Whole Antibodies, Produced by High Cell Density Fermentation of Escherichia Coli", Bio/Technology, 11: 1271-1277, 1993.			
	120	Petkova et al. "A Structural Model for Alzheimer's β -Amyloid Fibrils Based on Experimental Constraints From Solid State NMR", Proc. Natl. Acad. Sci. USA, 99(26): 16742-16747, 2002.			
	121	Pettmann et al. "Morphological and Biochemical Maturation of Neurons Cultured in the Absence of Glial Cells", Nature, 281: 378-380, 1979.			
	122	Pispisa et al. "A Spectroscopic and Molecular Mechanics Investigation on A Series of AIB-Based Linear Peptides and A Peptide Template, Both Containing Tryptophan and A Nitroxide Derivative as Probes", Biopolymers, 53: 169-181, 2000.			
	123	Porter "The Hydrolysis of Rabbit γ -Globulin and Antibodies With Crystalline Papain", Biochemical Journal, 73: 119-126, 1959.			
	124	Presta "Antibody Engineering", Current Opinion in Structural Biology, 2: 593-596, 1992.			
Examiner Signature	/Aditi Dutt/			Date Considered	11/21/2008

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional).

² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁷ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22311-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22311-1450.

Substitute for form 1449A/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/562,852
		Filing Date	April 19, 2006
		First Named Inventor	Ehud GAZIT
		Art Unit	1649
Examiner Name	DUTT, ADITI		
Sheet	10	Of	12
OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	
	125	Puchtler et al. "A Review of Early Concepts of Amyloid in Context With Contemporary Chemical Literature From 1839 to 1859", The Journal of Histochemistry and Cytochemistry, 14(2): 123-134, 1966.	
	126	Reches et al. "Amyloid Fibril Formation by Pentapeptide and Tetrapeptide Fragments of Human Calcitonin", The Journal of Biological Chemistry, 277(38): 35475-35480, 2002.	
	127	Reches et al. "Casting Metal Nanowires Within Discrete Self-Assembled Peptide Nanotubes", Science, 300(5619): 625-627, 2003, Abstract.	
	128	Reches et al. "Designed Aromatic Homo-Dipeptides: Formation of Ordered Nanostructures and Potential Nanotechnological Applications", Physical Biology, 3: S10-S19, 2006.	
	129	Reches et al. "Self-Assembly of Peptide Nanotubes and Amyloid-Like Structures by Charged-Termini-Capped Diphenylalanine Peptide Analogues", Israel Journal of Chemistry, 45(3): 363-371, 2005.	
	130	Reches et al. "Supporting Online Material", Science, 300(5619): 1-9, 2003. Retrieved From the Internet: URL: http://www.sciencemag.org/cgi/data/300/5619/625/DC1	
	131	Riechmann et al. "Reshaping Human Antibodies for Therapy", Nature, 332: 323-329, 1988.	
	132	Sacchettini et al. "Therapeutic Strategies for Human Amyloid Diseases", Nature Reviews: Drug Discovery, 1: 267-275, 2002.	
	133	Shetty et al. "Aromatic π -Stacking in Solution as Revealed Through the Aggregation of Phenylacetylene Macrocycles", Journal of the American Chemical Society, 118: 1019-1027, 1996.	
	134	Sigel-Causey et al. "Phylogeny of the Pelecaniformes: Molecular Systematics of A Privative Group", Avian Molecular Evolution and Systematics, academic Press, P.159-171, NBCI GenBank, Accession No. AAB58518, 1997.	
	135	Solomon et al. "Disaggregation of Alzheimer β -Amyloid by Site-Directed MAb", Proc. Natl. Acad. Sci. USA, 94: 4109-4112, 1997.	
	136	Stewart "Theoretical Aspects of Antibiotic Diffusion Into Microbial Biofilms", Antimicrobial Agents and Chemotherapy, 40(11): 2517-2522, 1996.	
Examiner Signature	/Aditi Dutt/		Date Considered 11/21/2008

* EXAMINER. Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered.

Include copy of copy of this form with next communication to applicant.

† Applicant's unique citation designation number (optional).

‡ See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

§ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

¶ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

|| Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

° Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number	10/562,852
		Filing Date	April 19, 2006
		First Named Inventor	Ehud GAZIT
		Art Unit	1649
		Examiner Name	DUTT, ADITI
Sheet	11	Of	12
		Attorney Docket Number	31230
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published	
	137	Sun et al. "Aromatic Van der Waals Clusters: Structure and Nonrigidity", Journal of Physical Chemistry, 100: 13348-13366, 1996.	
	138	Tjernberg et al. "Arrest of β -Amyloid Fibril Formation by A Pentapeptide Ligand", The Journal of Biological Chemistry, 271(15): 8545-8548, 1996.	
	139	Tjernberg et al. "Controlling Amyloid β -Peptide Fibril Formation With Protease-Stable Ligands", The Journal of Biological Chemistry, 272(19): 12601-12605, 1997.	
	140	Toledano et al. "Enzyme-Triggered Self-Assembly of Peptide Hydrogels Via Reversed Hydrolysis", Journal of the American Chemical Society, JACS, 128(4): 1070-1071, 2006.	
	141	Tonkinson et al. "Antisense Oligodeoxynucleotides as Clinical Therapeutic Agents", Cancer Investigation, 14(1): 54-65, 1996.	
	142	True et al. "Epigenetic Regulation of Translation Reveals Hidden Genetic Variation to Produce Complex Traits", Nature, 431: 184-187, 2004.	
	143	Tsai et al. "Synthesis of A β -Containing Peptidomimetics as Potential Inhibitors of Alzheimer's γ -Secretase", 218th ACS National Meeting, New Orleans, USA, Meeting Abstract, MEDI-018, 1999. Abstract.	
	144	Tsang et al. "A Simple Chemical Method of Opening and Filling Carbon Nanotubes", Nature, 372: 159-162, 1994.	
	145	Tuite et al. "Propagation of Yeast Prions", Nature Reviews, 4: 878-889, 2003.	
	146	Vauthey et al. "Molecular Self-Assembly of Surfactant-Like Peptides to Form Nanotubes and Nanovesicles", Proc. Natl. Acad. Sci. USA, 99(8): 5355-5360, 2002.	
	147	Verhoeyen et al. "Reshaping Human Antibodies: Grafting An Antilysozyme Activity", Science, 239: 1534-1536, 1988.	
	148	Vidal et al. "A Stop-Codon Mutation in the BR1 Gene Associated With Familial British Dementia", Nature, 399: 776-781, 1999.	
	149	Whitlow et al. "Single-Chain Fv Proteins and Their Fusion Proteins", Methods: A Companion to Methods in Enzymology, 2(2): 97-105, 1991.	
	150	Wolffenden et al. "Affinities of Amino Acid Side Chains for Solvent Water", Biochemistry, 20: 849-855, 1981.	
Examiner Signature	/Aditi Dutt/		Date Considered 11/21/2008

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered.

Include copy of copy of this form with next communication to applicant

† Applicant's unique citation designation number (optional)

2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3)

4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document

5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible.

6 Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

[illegible]

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional)

² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04, 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English language translation is attached

Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and) by the USPTO to process an application. Confidentiality is governed by 35 U.S.C. 422 and 37 CFR 1.4. This collection is estimated to take 2 hours to complete, including gathering, preparing, and reviewing the completed application form and the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22311-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22311-1450

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.